Compare NextEra Energy, Inc. (NEE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs BIO-TECHNE Corp — how do they compare? NextEra Energy, Inc. trades at $77.39 (market cap $161.39B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: NextEra Energy, Inc. is far larger — about 14.2× BIO-TECHNE Corp's market cap, and NextEra Energy, Inc. pays the higher dividend (3.22%). Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and BIO-TECHNE Corp for 63 Days on average.
| NEE | TECH | |
|---|---|---|
Market Cap | $161.39B | $11.36B |
Volume | 11,780,955 | 5,390,331 |
Sector | Utilities | Health |
52-Week High | $97.88 | $72.61 |
52-Week Low | $75.49 | $43.31 |
Typical Hold Time | 83 Days | 63 Days |
Enterprise Value | $268.72B | $11.39B |
Dividend Yield | 3.22% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $77.06, down 1.05% today, near its 52-week low of $74.78. The stock shows mixed signals with a bearish technical outlook but strong fundamentals, including a 32.4% net income margin and recent earnings beats. Recent news highlights growth initiatives like the Project Star energy infrastructure partnership and a dividend of $0.62 payable in September 2026.
NEE offers a compelling valuation with a P/E of 17.39 and a consensus price target of $96, implying 25% upside. Risks include high debt levels and interest rate sensitivity, but analyst sentiment remains bullish with 66.7% buy ratings. The stock is positioned for long-term growth in clean energy, though near-term volatility may persist.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
